

Let's Talk Type 1 Diabetes: Benefits of Early Detection, Screening, and Monitoring

TzielD[®]
(teplizumab-mzwv)
Injection | 2mg/2mL

INDICATION: TZIELD is a CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D.

You are cordially invited to a live program.



Program Objectives:

- Recognize key clinical characteristics of type 1 diabetes
- Identify best practices for screening and monitoring individuals at risk for type 1 diabetes
- Review clinical implications associated with the early detection of type 1 diabetes and eligibility for TZIELD



Speaker(s):

Swati V. Elchuri, MD
Pediatric Endocrinologist
Pediatric Diagnostic Center, Ventura County Health Care Agency
Thousand Oaks, CA



Date and Time:

10/7/2025
6:30 PM, Pacific Time



Location:

Larsen's Grill
590 Town Center Dr
Oxnard, CA,
93036



Registration Information:

RSVP to

Cheryl Lacsina
cheryl.lacsina@SanofiUSConnect.com
(310) 405-5669

Please RSVP by

October 2, 2025

INDICATION:

TZIELD[®] (teplizumab-mzwv) is a CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D.

IMPORTANT SAFETY INFORMATION:

Warnings and Precautions

Cytokine Release Syndrome (CRS): CRS occurred in TZIELD-treated patients during the treatment period and through 28 days after the last drug administration. Prior to TZIELD treatment, premedicate with antipyretics, antihistamines and/or antiemetics, and treat similarly if symptoms occur during treatment. If severe CRS develops, consider pausing dosing for 1 day to 2 days and administering the remaining doses to complete the full 14-day course on consecutive days; or discontinue treatment. Monitor liver enzymes during treatment. Discontinue TZIELD treatment in patients who develop elevated alanine aminotransferase or aspartate aminotransferase more than 5 times the upper limit of normal (ULN) or bilirubin more than 3 times ULN.

Please see additional Important Safety Information throughout and accompanying Prescribing Information, including patient selection criteria, and Medication Guide.

Prescribers and other Healthcare Professionals may go to
<https://www.sanofi.us/en/products-and-resources> for State Price Disclosure Information

© 2025 Sanofi. All rights reserved.
MAT-US-2502176-v3.0-04/2025

sanofi

Let's Talk Type 1 Diabetes: Benefits of Early Detection, Screening, and Monitoring



INDICATION: TZIELD is a CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D.

INDICATION:

TZIELD® (teplizumab-mzwv) is a CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D.

IMPORTANT SAFETY INFORMATION CON'T: WARNINGS AND PRECAUTIONS

- **Serious Infections:** Use of TZIELD is not recommended in patients with active serious infection or chronic infection other than localized skin infections. Monitor patients for signs and symptoms of infection during and after TZIELD administration. If serious infection develops, treat appropriately, and discontinue TZIELD.
- **Lymphopenia:** Lymphopenia occurred in most TZIELD-treated patients. For most patients, lymphocyte levels began to recover after the fifth day of treatment and returned to pretreatment values within two weeks after treatment completion and without dose interruption. Monitor white blood cell counts during the treatment period. If prolonged severe lymphopenia develops (<500 cells per mL lasting 1 week or longer), discontinue TZIELD.
- **Hypersensitivity Reactions:** Acute hypersensitivity reactions including serum sickness, angioedema, urticaria, rash, vomiting and bronchospasm occurred in TZIELD-treated patients. If severe hypersensitivity reactions occur, discontinue TZIELD and treat promptly.
- **Vaccinations:** The safety of immunization with live-attenuated (live) vaccines with TZIELD-treated patients has not been studied. TZIELD may interfere with immune response to vaccination and decrease vaccine efficacy. Administer all age-appropriate vaccinations prior to starting TZIELD.
 - Administer live vaccines at least 8 weeks prior to treatment. Live vaccines are not recommended during treatment, or up to 52 weeks after treatment.
 - Administer inactivated (killed) vaccines or mRNA vaccines at least 2 weeks prior to treatment. Inactivated vaccines are not recommended during treatment or 6 weeks after completion of treatment.

ADVERSE REACTIONS

- Most common adverse reactions (>10%) were lymphopenia, rash, leukopenia, and headache.

USE IN SPECIFIC POPULATIONS

- **Pregnancy:** May cause fetal harm.
- **Lactation:** A lactating woman may consider pumping and discarding breast milk during and for 20 days after TZIELD administration.

Please see full accompanying Prescribing Information, including patient selection criteria, and Medication Guide.

Several state laws set limits on or prohibit the provision of meals to healthcare professionals. If you have an active state license in certain states (e.g., Minnesota, New Jersey, or Vermont) and you accept this invitation and choose to attend this program, you must notify the host if you will not be able to accept the meal provided and document this on the Sign In Sheet ("Opt Out or Will Not Consume"). State limits/restrictions are on the Sign In Sheet. Per Sanofi policy and the PhRMA Code, appropriate attendees for speaker programs are, in sum, healthcare professionals for whom the content presented is relevant to their function and attendees who have a bona fide educational need for the information; guests and spouses are not permitted to attend.

No CME activity provided

TZIELD is manufactured by Provention Bio, a Sanofi Company
Prescribers and other Healthcare Professionals may go to
<https://www.sanofi.us/en/products-and-resources> for State Price Disclosure Information